MyFinsight
Home
Blog
About
Cash and cash
equivalents
$82,923K
(-61.77%↓ Y/Y)
Investments in marketable
securities
$22,383K
(7.90%↑ Y/Y)
Trade receivables,
net
$13,881K
(171.70%↑ Y/Y)
Inventory
$5,667K
(25.57%↑ Y/Y)
Other prepaids and
current assets
$5,354K
(-54.30%↓ Y/Y)
Prepaid manufacturing
$3,208K
(-52.12%↓ Y/Y)
Tsa receivables,
net
$372K
(-99.68%↓ Y/Y)
Total current assets
$133,788K
(-64.81%↓ Y/Y)
Intangible assets, net
$44,989K
(-14.00%↓ Y/Y)
Inventory, non-current
$8,425K
Other assets,
non-current
$3,116K
(-38.17%↓ Y/Y)
Property and equipment,
net
$865K
(-54.64%↓ Y/Y)
Total assets
$191,183K
(-56.50%↓ Y/Y)
Total liabilities and
stockholders' equity
$191,183K
(-56.50%↓ Y/Y)
Total liabilities
$130,345K
(-59.22%↓ Y/Y)
Total stockholders'
equity
$60,838K
(-49.23%↓ Y/Y)
Accumulated deficit
-$1,441,927K
(-10.09%↓ Y/Y)
Accumulated other
comprehensive loss
-$281K
(-2.18%↓ Y/Y)
Total current
liabilities
$75,510K
(-71.36%↓ Y/Y)
Term loan,
non-current
$37,247K
(1.03%↑ Y/Y)
Other liabilities,
non-current
$17,588K
(5.10%↑ Y/Y)
Additional paid-in capital
$1,503,031K
(5.12%↑ Y/Y)
Common stock (0.0001
par value shares...
$15K
(25.00%↑ Y/Y)
Tsa payables and
accrued liabilities
$22,660K
(-78.21%↓ Y/Y)
Accrued rebates, fees
and reserves
$14,894K
(-84.62%↓ Y/Y)
Accrued and other
current liabilities
$14,851K
(4.74%↑ Y/Y)
Accounts payable
$13,168K
(-65.00%↓ Y/Y)
Accrued compensation
$9,937K
(-9.79%↓ Y/Y)
Back
Back
Balance Sheet
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)
source: myfinsight.com